Search research articles
Contact Us
Filters
Showing results (61-70 of 88) with videos related to
Page
of 9
Sort By:
The Journal of Urology
|
August 20, 2008
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer
James L Gulley, Jeanny B Aragon-Ching, Seth M Steinberg, et al.
BJU International
|
January 22, 2009
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer
Jeanny B Aragon-Ching, Lokesh Jain, James L Gulley, et al.
The Lancet. Oncology
|
February 14, 2012
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Ravi A Madan, Mahsa Mohebtash, Philip M Arlen, et al.
Cancer Biology & Therapy
|
December 17, 2005
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors
William L Dahut, Nehal J Lakhani, James L Gulley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2004
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
William L Dahut, James L Gulley, Philip M Arlen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2004
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas
John L Marshall, James L Gulley, Philip M Arlen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 21, 2006
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
Philip M Arlen, James L Gulley, Catherine Parker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2010
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
Philip W Kantoff, Thomas J Schuetz, Brent A Blumenstein, et al.
The Journal of Urology
|
January 27, 2009
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation
William D Figg, Maha H Hussain, James L Gulley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2005
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
James L Gulley, Philip M Arlen, Anne Bastian, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 88) with videos related to
Sort By:
Page
of 9
The Journal of Urology
|
August 20, 2008
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer
James L Gulley, Jeanny B Aragon-Ching, Seth M Steinberg, et al.
BJU International
|
January 22, 2009
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer
Jeanny B Aragon-Ching, Lokesh Jain, James L Gulley, et al.
The Lancet. Oncology
|
February 14, 2012
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Ravi A Madan, Mahsa Mohebtash, Philip M Arlen, et al.
Cancer Biology & Therapy
|
December 17, 2005
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors
William L Dahut, Nehal J Lakhani, James L Gulley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2004
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
William L Dahut, James L Gulley, Philip M Arlen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2004
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas
John L Marshall, James L Gulley, Philip M Arlen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 21, 2006
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
Philip M Arlen, James L Gulley, Catherine Parker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2010
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
Philip W Kantoff, Thomas J Schuetz, Brent A Blumenstein, et al.
The Journal of Urology
|
January 27, 2009
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation
William D Figg, Maha H Hussain, James L Gulley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2005
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
James L Gulley, Philip M Arlen, Anne Bastian, et al.
Page
of 9